Evolus, Inc. (EOLS)
| Market Cap | 342.87M |
| Revenue (ttm) | 297.18M |
| Net Income (ttm) | -51.64M |
| Shares Out | 65.06M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 569,209 |
| Open | 5.22 |
| Previous Close | 5.22 |
| Day's Range | 5.20 - 5.38 |
| 52-Week Range | 3.86 - 12.28 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 15.50 (+194.12%) |
| Earnings Date | May 4, 2026 |
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newpo... [Read more]
Financial Performance
In 2025, Evolus's revenue was $297.18 million, an increase of 11.61% compared to the previous year's $266.27 million. Losses were -$51.64 million, 2.42% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 194.12% from the latest price.
News
Evolus Transcript: 25th Annual Needham Virtual Healthcare Conference
Mid-teens market share and double-digit growth were achieved in 2025, with international expansion and a new HA filler, Evolysse, strengthening the portfolio. The company expects continued growth, stable pricing, and profitability in 2026, with Sculpt poised as a key future driver.
Evolus to Report First Quarter Financial Results on May 4, 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during Mar...
Evolus Transcript: Leerink Global Healthcare Conference 2026
Toxin market recovery began in late 2023, with fillers lagging but showing positive signs, especially in the UK. Portfolio expansion, including a differentiated HA filler and upcoming Sculpt launch, is driving growth, supported by strong training, loyalty programs, and international expansion. 2026 revenue is guided at $327M-$337M, with further growth expected by 2028.
Evolus Earnings Call Transcript: Q4 2025
Delivered 12% revenue growth in 2025 and achieved Q4 profitability despite a rare market decline. Guidance for 2026 targets 10–13% revenue growth, stable margins, and sustained profitability, with new product launches and international expansion supporting future growth.
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financi...
Evolus to Participate in The Leerink Partners Global Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man...
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net...
Evolus Transcript: Stifel 2025 Healthcare Conference
Strong growth continues with Jeuveau and the rapid launch of Evolysse, supported by a robust financial position and expanding international presence. Market headwinds are being addressed through product differentiation, portfolio bundling, and innovation, with profitability targeted for Q4 2025 and a major portfolio expansion in 2026.
Evolus Earnings Call Transcript: Q3 2025
Q3 revenue grew 13% year-over-year, driven by Jeuveau and Evolysse, with strong consumer loyalty and expanding customer base. Gross margin remained robust, and the company is on track for profitability in Q4 2025, despite tariff risks and a challenging market.
Evolus Reports Third Quarter 2025 Financial Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial resu...
Evolus to Participate in 2025 Stifel Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man...
Evolus to Report Third Quarter Financial Results on November 5, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partn...
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qu...
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of...
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline r...
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submit...
Evolus Earnings Call Transcript: Q2 2025
Second quarter revenue grew 4% year-over-year, driven by Evolysse's strong launch and international expansion, despite Jeuveau's first-ever decline amid a challenging U.S. market. Cost structure was optimized, guidance was reset, and profitability is targeted for 2026.
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial resu...
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of...
Evolus to Report Second Quarter Financial Results on August 5, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered w...